

**AUGTYRO
(repotrectinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
 - a. 18 years of age or older
 - b. ROS1-positive
2. Solid tumors
 - a. 12 years of age or older
 - b. Neurotrophic tyrosine receptor kinase (NTRK) gene fusion
 - c. Locally advanced **OR** metastatic **OR** surgical resection is likely to result in severe morbidity
 - d. Disease has progressed following treatment **OR** patient has no satisfactory alternative therapy

AND ALL of the following for **ALL** indications:

- a. ROS1-positive
- b. Prescriber agrees to monitor uric acid level and liver function tests (LFTs) including bilirubin
- c. Female patients of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Augtyro and for 2 months after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Augtyro and for 4 months after the last dose

Prior - Approval Limits

Quantity 320 mg per day

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnoses



**BlueCross
BlueShield**

Federal Employee Program.

AUGTYRO (repotrectinib)

Patient must have **ONE** of the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
 - a. 18 years of age or older
2. Solid tumors
 - a. 12 years of age or older

AND ALL of the following for **ALL** indications:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor uric acid level and liver function tests (LFTs) including bilirubin
- c. Female patients of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Augtyro and for 2 months after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Augtyro and for 4 months after the last dose

Prior - Approval *Renewal* Limits

Same as above